STOP2030 is an international partnership focused on bringing innovation to the treatment of intestinal worms. With over 5 years of research, they have developed a new two-in-one medicine for helminthiasis, aiming to provide a more effective solution for soil-transmitted helminth infections. By combining two existing drugs into one pill, they have created a formulation that targets all five species of intestinal worms, reducing the risk of drug resistance.

The project, backed by public-private partnerships and a diverse consortium of experts, is dedicated to translating research into action. Through clinical trials and collaborations with countries like Kenya and Ghana, STOP2030 is working towards making their co-formulation safe, accessible, and affordable for mass drug administration campaigns. Stay updated on their progress through their latest news and join their global effort to combat intestinal worm infections.